Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PB9720 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-LOXL2 Antibody Picoband™
- Antibody type
- Polyclonal
- Description
- Polyclonal antibody for LYSYL OXIDASE LIKE 2/LOXL2 detection. Host: Rabbit.Size: 100μg/vial. Tested applications: WB. Reactive species: Human. LYSYL OXIDASE LIKE 2/LOXL2 information: Molecular Weight: 86725 MW; Subcellular Localization: Secreted, extracellular space, extracellular matrix, basement membrane . Nucleus. Chromosome. Associated with chromatin. It is unclear how LOXL2 is nuclear: it contains a clear signal sequence and is predicted to localize in the extracellular medium. However, different reports confirmed the intracellular location and its key role in transcription regulation; Tissue Specificity: Expressed in many tissues. Highest expression in reproductive tissues, placenta, uterus and prostate. Up- regulated in a number of cancers cells and tissues.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Vial size
- 100μg/vial
- Concentration
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquoted and stored frozen at -20°C for a longer time. Avoid repeated freezing and thawing.
- Handling
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
Submitted references Phosphorylation of AKT by lysyl oxidase-like 2 activates the PI3K/AKT signaling pathway to promote proliferation, invasion and metastasis in esophageal squamous carcinoma.
Fan Z, Liu Y, Liu X, Nian W, Huang X, Yang Q, Hou S, Chen F
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023 Aug;25(8):2487-2498
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023 Aug;25(8):2487-2498
No comments: Submit comment
No validations: Submit validation data